PlusPedia wird derzeit technisch modernisiert. Aktuell laufen Wartungsarbeiten. Für etwaige Unannehmlichkeiten bitten wir um Entschuldigung; es sind aber alle Artikel zugänglich und Sie können PlusPedia genauso nutzen wie immer.
Neue User bitte dringend diese Hinweise lesen:
Anmeldung - E-Mail-Adresse Neue Benutzer benötigen ab sofort eine gültige Email-Adresse. Wenn keine Email ankommt, meldet Euch bitte unter NewU25@PlusPedia.de.
Hinweis zur Passwortsicherheit:
Bitte nutzen Sie Ihr PlusPedia-Passwort nur bei PlusPedia.
Wenn Sie Ihr PlusPedia-Passwort andernorts nutzen, ändern Sie es bitte DORT bis unsere Modernisierung abgeschlossen ist.
Überall wo es sensibel, sollte man generell immer unterschiedliche Passworte verwenden! Das gilt hier und im gesamten Internet.
Aus Gründen der Sicherheit (PlusPedia hatte bis 24.07.2025 kein SSL | https://)
Bei PlusPedia sind Sie sicher: – Wir verarbeiten keine personenbezogenen Daten, erlauben umfassend anonyme Mitarbeit und erfüllen die Datenschutz-Grundverordnung (DSGVO) vollumfänglich. Es haftet der Vorsitzende des Trägervereins.
PlusPedia blüht wieder auf als freundliches deutsches Lexikon.
Wir haben auf die neue Version 1.43.3 aktualisiert.
Wir haben SSL aktiviert.
Hier geht es zu den aktuellen Aktuelle Ereignissen
Lunge (Neubildung NSCLC): Unterschied zwischen den Versionen
Zur Navigation springen
Zur Suche springen
KKeine Bearbeitungszusammenfassung |
KKeine Bearbeitungszusammenfassung |
||
| (Eine dazwischenliegende Version desselben Benutzers wird nicht angezeigt) | |||
| Zeile 5: | Zeile 5: | ||
|- | |- | ||
| bgcolor="#dfdfdf" | '''Freie Übersichtsartikel''' | | bgcolor="#dfdfdf" | '''Freie Übersichtsartikel''' | ||
| align="left" width="800" |<ref name="PMID19893597">Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama 63(5):223-30 (2009) PMID 19893597 </ref><ref name="PMID18832554">Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Am J Respir Crit Care Med 178(8):783-5 (2008) PMID 18832554 </ref><ref name="PMID19956424">Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res 1(2):101-14 (2009) PMID 19956424 </ref><ref name="PMID19704160">Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 20(9):1455-7 (2009) PMID 19704160 </ref><ref name="PMID19454467">Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4():68-70 (2009) PMID 19454467 </ref><ref name="PMID18790931">Challenges treating older non-small cell lung cancer patients. Ann Oncol 19 Suppl 7():vii109-13 (2008) PMID 18790931 </ref><ref name="PMID18456762">Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2():ii39-40 (2008) PMID 18456762 </ref><ref name="PMID19262443">The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15(1):4-9 (2009) PMID 19262443 </ref><ref name="PMID19262442">Current status and future direction of surgical treatment for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 15(1):1-3 (2009) PMID 19262442 </ref><ref name="PMID20835310">Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Ann Thorac Med 5(3):153-60 (2010) PMID 20835310 </ref><ref name="PMID19881166">Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients. Ann Thorac Med 4(4):201-7 (2009) PMID 19881166 </ref><ref name="PMID5058">Surface balance study of the interaction between microorganisms and lipid monolayer at the air/water interface. Appl Environ Microbiol 31(4):609-11 (1976) PMID 5058 </ref><ref name="PMID20859451">Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 4():237-43 (2010) PMID 20859451 </ref><ref name="PMID20531966">Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics 4():83-90 (2010) PMID 20531966 </ref><ref name="PMID19707410">EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 3():215-24 (2009) PMID 19707410 </ref><ref name="PMID18831719">First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc 2 Suppl 2():S3 (2008) PMID 18831719 </ref><ref name="PMID19503669">The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg 52(3):235-42 (2009) PMID 19503669 </ref><ref name="PMID19551884">Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115(18):4156-66 (2009) PMID 19551884 </ref><ref name="PMID19658185">Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 115(22):5143-54 (2009) PMID 19658185 </ref><ref name="PMID19235250">Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250 </ref><ref name="PMID18286507">Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112(5):1106-13 (2008) PMID 18286507 </ref><ref name="PMID19182534">Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther 8(3):206-12 (2009) PMID 19182534 </ref><ref name="PMID19680652">Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65(6):1023-8 (2010) PMID 19680652 </ref><ref name="PMID18824424">Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging 8():181-5 (2008) PMID 18824424 </ref><ref name="PMID18852078">PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging 8 Spec No A():S27-31 (2008) PMID 18852078 </ref><ref name="PMID18331970">Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging 8():27-35 (2008) PMID 18331970 </ref><ref name="PMID20062690">Acute cholangitis due to pancreatic metastasis from squamous cell lung carcinoma: a case report and review of literature. Cases J 2():9113 (2009) PMID 20062690 </ref><ref name="PMID19809052">Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 136(4):1112-8 (2009) PMID 19809052 </ref><ref name="PMID19225067">Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135(6):1596-609 (2009) PMID 19225067 </ref><ref name="PMID19584208">The new lung cancer staging system. Chest 136(1):260-71 (2009) PMID 19584208 </ref><ref name="PMID18321899">Staging of lung cancer. Chest 133(3):593-5 (2008) PMID 18321899 </ref><ref name="PMID19447868">Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9 (2009) PMID 19447868 </ref><ref name="PMID19531624">Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493-8 (2009) PMID 19531624 </ref><ref name="PMID20008850">***ENG*** Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15(24):7502-7509 (2009) PMID 20008850 </ref><ref name="PMID19671872">Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15(16):5040-8 (2009) PMID 19671872 </ref><ref name="PMID18981003">Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14(21):7060-7 (2008) PMID 18981003 </ref><ref name="PMID18483355">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10):2895-9 (2008) PMID 18483355 </ref><ref name="PMID19808188">The role for surgery in stage III non-small-cell lung cancer: can we reliably select the right patients? Clin Lung Cancer 10(5):314-6 (2009) PMID 19808188 </ref><ref name="PMID19443337">Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 10(3):174-9 (2009) PMID 19443337 </ref><ref name="PMID19443335">Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer 10(3):158-67 (2009) PMID 19443335 </ref><ref name="PMID19362956">Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956 </ref><ref name="PMID19362951">Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 10(2):91-8 (2009) PMID 19362951 </ref><ref name="PMID19632948">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281-9 (2009) PMID 19632948 </ref><ref name="PMID19289369">Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28-35 (2009) PMID 19289369 </ref><ref name="PMID19289368">Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10(1):20-7 (2009) PMID 19289368 </ref><ref name="PMID19073514">New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. Clin Lung Cancer 9(6):326-30 (2008) PMID 19073514 </ref><ref name="PMID18621622">Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer 9(3):141-3 (2008) PMID 18621622 </ref><ref name="PMID18650168">Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer. Clin Lung Cancer 9(4):213-6 (2008) PMID 18650168 </ref><ref name="PMID19546457">Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180(13):1326-8 (2009) PMID 19546457 </ref><ref name="PMID20404973">Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17(2):13-23 (2010) PMID 20404973 </ref><ref name="PMID19672420">Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 16(4):9-21 (2009) PMID 19672420 </ref><ref name="PMID19079629">Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 15(6):279-85 (2008) PMID 19079629 </ref><ref name="PMID20515609">Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. Discov Med 9(48):411-7 (2010) PMID 20515609 </ref><ref name="PMID20587343">Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 9(49):538-45 (2010) PMID 20587343 </ref><ref name="PMID20038979">Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int 106(49):809-18; quiz 819-20 (2009) PMID 20038979 </ref><ref name="PMID19629205">Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int 105(14):249-54 (2008) PMID 19629205 </ref><ref name="PMID19118231">Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33(1):201-12 (2009) PMID 19118231 </ref><ref name="PMID19336594">First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33(4):915-30 (2009) PMID 19336594 </ref><ref name="PMID21047494">Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):71-9 (2010) PMID 21047494 </ref><ref name="PMID21047489">Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489 </ref><ref name="PMID20507803">Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803 </ref><ref name="PMID19567213">Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess 13 Suppl 1():41-7 (2009) PMID 19567213 </ref><ref name="PMID18645621">Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5(4):209-17 (2008) PMID 18645621 </ref><ref name="PMID20354037">In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg 10(6):1015-21 (2010) PMID 20354037 </ref><ref name="PMID19155223">Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg 8(4):467-73 (2009) PMID 19155223 </ref><ref name="PMID19917871">American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-66 (2009) PMID 19917871 </ref><ref name="PMID20433767">Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3():18 (2010) PMID 20433767 </ref><ref name="PMID19159467">Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2():2 (2009) PMID 19159467 </ref><ref name="PMID19380411">Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1():31S-42S (2009) PMID 19380411 </ref><ref name="PMID20539732">American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 6(1):39-43 (2010) PMID 20539732 </ref><ref name="PMID20539725">Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6(1):12-8 (2010) PMID 20539725 </ref><ref name="PMID20551407">Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 303(23):2368-76 (2010) PMID 20551407 </ref><ref name="PMID19088154">Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 39(3):137-50 (2009) PMID 19088154 </ref><ref name="PMID20338627">Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722):1267-77 (2010) PMID 20338627 </ref><ref name="PMID18452692">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584-94 (2008) PMID 18452692 </ref><ref name="PMID18437168">Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 Suppl 2():S16-22 (2008) PMID 18437168 </ref><ref name="PMID20616912">Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther 2():251-60 (2009) PMID 20616912 </ref><ref name="PMID19680293">Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1():S24-31 (2009) PMID 19680293 </ref><ref name="PMID19726457">Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14(9):909-20 (2009) PMID 19726457 </ref><ref name="PMID19892771">The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14(11):1116-30 (2009) PMID 19892771 </ref><ref name="PMID19423674">Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674 </ref><ref name="PMID19221167">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167 </ref><ref name="PMID19482958">Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14(6):601-11 (2009) PMID 19482958 </ref><ref name="PMID19474164">Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612-20 (2009) PMID 19474164 </ref><ref name="PMID19357226">Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4):399-411 (2009) PMID 19357226 </ref><ref name="PMID19349511">Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14(4):378-90 (2009) PMID 19349511 </ref><ref name="PMID19342473">The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist 14(4):412-24 (2009) PMID 19342473 </ref><ref name="PMID18779538">Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 13(9):945-53 (2008) PMID 18779538 </ref><ref name="PMID18997180">Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76 (2008) PMID 18997180 </ref><ref name="PMID18378542">Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13(3):309-19 (2008) PMID 18378542 </ref><ref name="PMID18586925">Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. Oncologist 13(6):700-8 (2008) PMID 18586925 </ref><ref name="PMID18263773">Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1():37-46 (2008) PMID 18263773 </ref><ref name="PMID18263772">Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1():28-36 (2008) PMID 18263772 </ref><ref name="PMID18263771">Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13 Suppl 1():21-7 (2008) PMID 18263771 </ref><ref name="PMID18263770">Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1():14-20 (2008) PMID 18263770 </ref><ref name="PMID18263769">Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769 </ref><ref name="PMID21165163">***ENG*** EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497-514 (2010) PMID 21165163 </ref><ref name="PMID19102716">EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10(1):59-68 (2009) PMID 19102716 </ref><ref name="PMID18056854">Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology 246(2):596-604 (2008) PMID 18056854 </ref><ref name="PMID18552311">Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248(2):632-42 (2008) PMID 18552311 </ref><ref name="PMID18539889">Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248(2):643-54 (2008) PMID 18539889 </ref><ref name="PMID18343515">Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87(1):17-23 (2008) PMID 18343515 </ref><ref name="PMID19027463">Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 35(6):590-6 (2008) PMID 19027463 </ref><ref name="PMID21070081">CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 9(6):589-96 (2010) PMID 21070081 </ref><ref name="PMID19014447">Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature. World J Surg Oncol 6():120 (2008) PMID 19014447 </ref><ref name="PMID16470272">Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35(1):33-7 (2006) PMID 16470272 </ref><ref name="PMID20595452">Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 22(1):132-8 (2011) PMID 20595452 </ref><ref name="PMID20150572">Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-9 (2010) PMID 20150572 </ref><ref name="PMID19690055">Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. Ann Oncol 20(10):1747-8 (2009) PMID 19690055 </ref><ref name="PMID19164456">Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20(5):835-41 (2009) PMID 19164456 </ref><ref name="PMID19150937">Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20(5):850-6 (2009) PMID 19150937 </ref><ref name="PMID17938425">Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19(1):115-22 (2008) PMID 17938425 </ref><ref name="PMID18096565">Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19(4):739-45 (2008) PMID 18096565 </ref><ref name="PMID17351253">Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol 18(5):903-8 (2007) PMID 17351253 </ref><ref name="PMID17322539">The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453-60 (2007) PMID 17322539 </ref><ref name="PMID17043094">Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18(1):110-5 (2007) PMID 17043094 </ref><ref name="PMID17079694">Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317-23 (2007) PMID 17079694 </ref><ref name="PMID17071935">Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18(2):324-30 (2007) PMID 17071935 </ref><ref name="PMID16807472">Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 17 Suppl 5():v86-90 (2006) PMID 16807472 </ref><ref name="PMID16807471">Non-platinum combination of gemcitabine in NSCLC. Ann Oncol 17 Suppl 5():v82-5 (2006) PMID 16807471 </ref><ref name="PMID16807470">Non-small-cell lung cancer: which platinum for gemcitabine? Ann Oncol 17 Suppl 5():v79-81 (2006) PMID 16807470 </ref><ref name="PMID16807469">Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 Suppl 5():v72-8 (2006) PMID 16807469 </ref><ref name="PMID16807466">First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17 Suppl 5():v64-7 (2006) PMID 16807466 </ref><ref name="PMID16807459">Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 Suppl 5():v29-32 (2006) PMID 16807459 </ref><ref name="PMID16608986">Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 17 Suppl 2():ii58-60 (2006) PMID 16608986 </ref><ref name="PMID16670205">A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17(7):1128-33 (2006) PMID 16670205 </ref><ref name="PMID16766586">Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol 17(12):1743-7 (2006) PMID 16766586 </ref><ref name="PMID12562651">Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14(2):242-7 (2003) PMID 12562651 </ref><ref name="PMID11822767">Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12(11):1651-2 (2001) PMID 11822767 </ref><ref name="PMID11106124">Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10):1335-41 (2000) PMID 11106124 </ref><ref name="PMID11142482">Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 11(11):1421-6 (2000) PMID 11142482 </ref><ref name="PMID9636840">A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9(4):457-9 (1998) PMID 9636840 </ref><ref name="PMID20723210">In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 10():441 (2010) PMID 20723210 </ref><ref name="PMID18212755">First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer 98(3):558-63 (2008) PMID 18212755 </ref><ref name="PMID17595658">Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97(3):283-9 (2007) PMID 17595658 </ref><ref name="PMID15266334">Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91(3):489-97 (2004) PMID 15266334 </ref><ref name="PMID12966418">Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89(6):1013-21 (2003) PMID 12966418 </ref><ref name="PMID14676793">Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer 89(12):2190-6 (2003) PMID 14676793 </ref><ref name="PMID12373594">Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87(8):825-33 (2002) PMID 12373594 </ref><ref name="PMID10945489">Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83(4):447-53 (2000) PMID 10945489 </ref><ref name="PMID10362105">Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80(7):981-90 (1999) PMID 10362105 </ref><ref name="PMID19235250">Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250 </ref><ref name="PMID17823908">Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110(9):2027-34 (2007) PMID 17823908 </ref><ref name="PMID17238182">Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer 109(4):727-31 (2007) PMID 17238182 </ref><ref name="PMID12712478">Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97(9):2242-7 (2003) PMID 12712478 </ref><ref name="PMID12879472">Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3):542-53 (2003) PMID 12879472 </ref><ref name="PMID11443620">Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92(1):146-52 (2001) PMID 11443620 </ref><ref name="PMID10526274">Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 86(8):1463-9 (1999) PMID 10526274 </ref><ref name="PMID19688117">Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study. Cancer Res Treat 40(3):116-20 (2008) PMID 19688117 </ref><ref name="PMID15764752">Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 127(3):738-47 (2005) PMID 15764752 </ref><ref name="PMID16002926">Chemotherapy for non-small cell lung cancer in elderly patients. Chest 128(1):132-9 (2005) PMID 16002926 </ref><ref name="PMID16100191">Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128(2):947-57 (2005) PMID 16100191 </ref><ref name="PMID18594002">A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14(13):4213-8 (2008) PMID 18594002 </ref><ref name="PMID15297403">Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10(15):5022-6 (2004) PMID 15297403 </ref><ref name="PMID19362956">Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956 </ref><ref name="PMID19289373">Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. Clin Lung Cancer 10(1):53-7 (2009) PMID 19289373 </ref><ref name="PMID18824450">Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 9(5):280-4 (2008) PMID 18824450 </ref><ref name="PMID18650174">An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9(4):235-8 (2008) PMID 18650174 </ref><ref name="PMID14653862">Gemcitabine/carboplatin in advanced non-small-cell lung cancer: data from randomized phase III trials. Clin Lung Cancer 4(2):76-9 (2002) PMID 14653862 </ref><ref name="PMID14662032">The value of platinum compounds in non-small-cell lung cancer. Clin Lung Cancer 3(4):249-53 (2002) PMID 14662032 </ref><ref name="PMID14720349">Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer 3 Suppl 1():S10-6 (2002) PMID 14720349 </ref><ref name="PMID14725730">Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review. Clin Lung Cancer 2 Suppl 1():S11-4 (2000) PMID 14725730 </ref><ref name="PMID20040271">Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204-9 (2009) PMID 20040271 </ref><ref name="PMID110590">A novel SH-type carboxypeptidase in the inner membrane of rat-liver mitochondria. Eur J Biochem 96(1):9-15 (1979) PMID 110590 </ref><ref name="PMID17690124">Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30(6):1186-92 (2007) PMID 17690124 </ref><ref name="PMID16481384">Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 27(5):895-901 (2006) PMID 16481384 </ref><ref name="PMID21047489">Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489 </ref><ref name="PMID20507803">Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803 </ref><ref name="PMID12618501">Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95(5):362-72 (2003) PMID 12618501 </ref><ref name="PMID18827606">Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-8 (2008) PMID 18827606 </ref><ref name="PMID15795320">Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110-8 (2005) PMID 15795320 </ref><ref name="PMID20616908">Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2():209-17 (2009) PMID 20616908 </ref><ref name="PMID19737998">Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14(9):930-5 (2009) PMID 19737998 </ref><ref name="PMID19423674">Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674 </ref><ref name="PMID19221167">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167 </ref><ref name="PMID18263769">Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769 </ref><ref name="PMID17470688">Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12(4):451-64 (2007) PMID 17470688 </ref><ref name="PMID16368866">Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3():1-10 (2005) PMID 16368866 </ref><ref name="PMID10394591">Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4(3):241-51 (1999) PMID 10394591 </ref><ref name="PMID16601104">Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 103(16):6332-7 (2006) PMID 16601104 </ref><ref name="PMID18827853">Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4(3):579-85 (2008) PMID 18827853 </ref> | | align="left" width="800" |<ref name="PMID19893597">Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama 63(5):223-30 (2009) PMID 19893597 </ref><ref name="PMID18832554">Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Am J Respir Crit Care Med 178(8):783-5 (2008) PMID 18832554 </ref><ref name="PMID19956424">Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res 1(2):101-14 (2009) PMID 19956424 </ref><ref name="PMID19704160">Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 20(9):1455-7 (2009) PMID 19704160 </ref><ref name="PMID19454467">Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4():68-70 (2009) PMID 19454467 </ref><ref name="PMID18790931">Challenges treating older non-small cell lung cancer patients. Ann Oncol 19 Suppl 7():vii109-13 (2008) PMID 18790931 </ref><ref name="PMID18456762">Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2():ii39-40 (2008) PMID 18456762 </ref><ref name="PMID19262443">The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15(1):4-9 (2009) PMID 19262443 </ref><ref name="PMID19262442">Current status and future direction of surgical treatment for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 15(1):1-3 (2009) PMID 19262442 </ref><ref name="PMID20835310">Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Ann Thorac Med 5(3):153-60 (2010) PMID 20835310 </ref><ref name="PMID19881166">Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients. Ann Thorac Med 4(4):201-7 (2009) PMID 19881166 </ref><ref name="PMID5058">Surface balance study of the interaction between microorganisms and lipid monolayer at the air/water interface. Appl Environ Microbiol 31(4):609-11 (1976) PMID 5058 </ref><ref name="PMID20859451">Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 4():237-43 (2010) PMID 20859451 </ref><ref name="PMID20531966">Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics 4():83-90 (2010) PMID 20531966 </ref><ref name="PMID19707410">EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 3():215-24 (2009) PMID 19707410 </ref><ref name="PMID18831719">First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc 2 Suppl 2():S3 (2008) PMID 18831719 </ref><ref name="PMID19503669">The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg 52(3):235-42 (2009) PMID 19503669 </ref><ref name="PMID19551884">Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115(18):4156-66 (2009) PMID 19551884 </ref><ref name="PMID19658185">Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 115(22):5143-54 (2009) PMID 19658185 </ref><ref name="PMID19235250">Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250 </ref><ref name="PMID18286507">Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112(5):1106-13 (2008) PMID 18286507 </ref><ref name="PMID19182534">Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther 8(3):206-12 (2009) PMID 19182534 </ref><ref name="PMID19680652">Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65(6):1023-8 (2010) PMID 19680652 </ref><ref name="PMID18824424">Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging 8():181-5 (2008) PMID 18824424 </ref><ref name="PMID18852078">PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging 8 Spec No A():S27-31 (2008) PMID 18852078 </ref><ref name="PMID18331970">Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging 8():27-35 (2008) PMID 18331970 </ref><ref name="PMID20062690">Acute cholangitis due to pancreatic metastasis from squamous cell lung carcinoma: a case report and review of literature. Cases J 2():9113 (2009) PMID 20062690 </ref><ref name="PMID19809052">Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 136(4):1112-8 (2009) PMID 19809052 </ref><ref name="PMID19225067">Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135(6):1596-609 (2009) PMID 19225067 </ref><ref name="PMID19584208">The new lung cancer staging system. Chest 136(1):260-71 (2009) PMID 19584208 </ref><ref name="PMID18321899">Staging of lung cancer. Chest 133(3):593-5 (2008) PMID 18321899 </ref><ref name="PMID19447868">Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9 (2009) PMID 19447868 </ref><ref name="PMID19531624">Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493-8 (2009) PMID 19531624 </ref><ref name="PMID20008850">***ENG*** Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15(24):7502-7509 (2009) PMID 20008850 </ref><ref name="PMID19671872">Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15(16):5040-8 (2009) PMID 19671872 </ref><ref name="PMID18981003">Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14(21):7060-7 (2008) PMID 18981003 </ref><ref name="PMID18483355">Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10):2895-9 (2008) PMID 18483355 </ref><ref name="PMID19808188">The role for surgery in stage III non-small-cell lung cancer: can we reliably select the right patients? Clin Lung Cancer 10(5):314-6 (2009) PMID 19808188 </ref><ref name="PMID19443337">Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 10(3):174-9 (2009) PMID 19443337 </ref><ref name="PMID19443335">Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer 10(3):158-67 (2009) PMID 19443335 </ref><ref name="PMID19362956">Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956 </ref><ref name="PMID19362951">Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 10(2):91-8 (2009) PMID 19362951 </ref><ref name="PMID19632948">Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281-9 (2009) PMID 19632948 </ref><ref name="PMID19289369">Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28-35 (2009) PMID 19289369 </ref><ref name="PMID19289368">Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10(1):20-7 (2009) PMID 19289368 </ref><ref name="PMID19073514">New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. Clin Lung Cancer 9(6):326-30 (2008) PMID 19073514 </ref><ref name="PMID18621622">Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer 9(3):141-3 (2008) PMID 18621622 </ref><ref name="PMID18650168">Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer. Clin Lung Cancer 9(4):213-6 (2008) PMID 18650168 </ref><ref name="PMID19546457">Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180(13):1326-8 (2009) PMID 19546457 </ref><ref name="PMID20404973">Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17(2):13-23 (2010) PMID 20404973 </ref><ref name="PMID19672420">Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 16(4):9-21 (2009) PMID 19672420 </ref><ref name="PMID19079629">Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 15(6):279-85 (2008) PMID 19079629 </ref><ref name="PMID20515609">Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. Discov Med 9(48):411-7 (2010) PMID 20515609 </ref><ref name="PMID20587343">Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 9(49):538-45 (2010) PMID 20587343 </ref><ref name="PMID20038979">Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int 106(49):809-18; quiz 819-20 (2009) PMID 20038979 </ref><ref name="PMID19629205">Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int 105(14):249-54 (2008) PMID 19629205 </ref><ref name="PMID19118231">Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33(1):201-12 (2009) PMID 19118231 </ref><ref name="PMID19336594">First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33(4):915-30 (2009) PMID 19336594 </ref><ref name="PMID21047494">Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):71-9 (2010) PMID 21047494 </ref><ref name="PMID21047489">Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489 </ref><ref name="PMID20507803">Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803 </ref><ref name="PMID19567213">Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess 13 Suppl 1():41-7 (2009) PMID 19567213 </ref><ref name="PMID18645621">Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5(4):209-17 (2008) PMID 18645621 </ref><ref name="PMID20354037">In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg 10(6):1015-21 (2010) PMID 20354037 </ref><ref name="PMID19155223">Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg 8(4):467-73 (2009) PMID 19155223 </ref><ref name="PMID19917871">American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-66 (2009) PMID 19917871 </ref><ref name="PMID20433767">Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3():18 (2010) PMID 20433767 </ref><ref name="PMID19159467">Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2():2 (2009) PMID 19159467 </ref><ref name="PMID19380411">Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1():31S-42S (2009) PMID 19380411 </ref><ref name="PMID20539732">American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 6(1):39-43 (2010) PMID 20539732 </ref><ref name="PMID20539725">Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6(1):12-8 (2010) PMID 20539725 </ref><ref name="PMID20551407">Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 303(23):2368-76 (2010) PMID 20551407 </ref><ref name="PMID19088154">Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 39(3):137-50 (2009) PMID 19088154 </ref><ref name="PMID20338627">Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722):1267-77 (2010) PMID 20338627 </ref><ref name="PMID18452692">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584-94 (2008) PMID 18452692 </ref><ref name="PMID18437168">Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 Suppl 2():S16-22 (2008) PMID 18437168 </ref><ref name="PMID20616912">Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther 2():251-60 (2009) PMID 20616912 </ref><ref name="PMID19680293">Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1():S24-31 (2009) PMID 19680293 </ref><ref name="PMID19726457">Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14(9):909-20 (2009) PMID 19726457 </ref><ref name="PMID19892771">The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14(11):1116-30 (2009) PMID 19892771 </ref><ref name="PMID19423674">Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674 </ref><ref name="PMID19221167">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167 </ref><ref name="PMID19482958">Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14(6):601-11 (2009) PMID 19482958 </ref><ref name="PMID19474164">Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612-20 (2009) PMID 19474164 </ref><ref name="PMID19357226">Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4):399-411 (2009) PMID 19357226 </ref><ref name="PMID19349511">Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14(4):378-90 (2009) PMID 19349511 </ref><ref name="PMID19342473">The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist 14(4):412-24 (2009) PMID 19342473 </ref><ref name="PMID18779538">Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 13(9):945-53 (2008) PMID 18779538 </ref><ref name="PMID18997180">Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76 (2008) PMID 18997180 </ref><ref name="PMID18378542">Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13(3):309-19 (2008) PMID 18378542 </ref><ref name="PMID18586925">Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. Oncologist 13(6):700-8 (2008) PMID 18586925 </ref><ref name="PMID18263773">Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1():37-46 (2008) PMID 18263773 </ref><ref name="PMID18263772">Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1():28-36 (2008) PMID 18263772 </ref><ref name="PMID18263771">Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13 Suppl 1():21-7 (2008) PMID 18263771 </ref><ref name="PMID18263770">Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1():14-20 (2008) PMID 18263770 </ref><ref name="PMID18263769">Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769 </ref><ref name="PMID21165163">***ENG*** EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497-514 (2010) PMID 21165163 </ref><ref name="PMID19102716">EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10(1):59-68 (2009) PMID 19102716 </ref><ref name="PMID18056854">Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology 246(2):596-604 (2008) PMID 18056854 </ref><ref name="PMID18552311">Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248(2):632-42 (2008) PMID 18552311 </ref><ref name="PMID18539889">Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248(2):643-54 (2008) PMID 18539889 </ref><ref name="PMID18343515">Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87(1):17-23 (2008) PMID 18343515 </ref><ref name="PMID19027463">Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 35(6):590-6 (2008) PMID 19027463 </ref><ref name="PMID21070081">CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 9(6):589-96 (2010) PMID 21070081 </ref><ref name="PMID19014447">Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature. World J Surg Oncol 6():120 (2008) PMID 19014447 </ref><ref name="PMID16470272">Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35(1):33-7 (2006) PMID 16470272 </ref><ref name="PMID20595452">Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 22(1):132-8 (2011) PMID 20595452 </ref><ref name="PMID20150572">Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-9 (2010) PMID 20150572 </ref><ref name="PMID19690055">Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. Ann Oncol 20(10):1747-8 (2009) PMID 19690055 </ref><ref name="PMID19164456">Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20(5):835-41 (2009) PMID 19164456 </ref><ref name="PMID19150937">Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20(5):850-6 (2009) PMID 19150937 </ref><ref name="PMID17938425">Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19(1):115-22 (2008) PMID 17938425 </ref><ref name="PMID18096565">Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19(4):739-45 (2008) PMID 18096565 </ref><ref name="PMID17351253">Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol 18(5):903-8 (2007) PMID 17351253 </ref><ref name="PMID17322539">The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453-60 (2007) PMID 17322539 </ref><ref name="PMID17043094">Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18(1):110-5 (2007) PMID 17043094 </ref><ref name="PMID17079694">Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317-23 (2007) PMID 17079694 </ref><ref name="PMID17071935">Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18(2):324-30 (2007) PMID 17071935 </ref><ref name="PMID16807472">Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 17 Suppl 5():v86-90 (2006) PMID 16807472 </ref><ref name="PMID16807471">Non-platinum combination of gemcitabine in NSCLC. Ann Oncol 17 Suppl 5():v82-5 (2006) PMID 16807471 </ref><ref name="PMID16807470">Non-small-cell lung cancer: which platinum for gemcitabine? Ann Oncol 17 Suppl 5():v79-81 (2006) PMID 16807470 </ref><ref name="PMID16807469">Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 Suppl 5():v72-8 (2006) PMID 16807469 </ref><ref name="PMID16807466">First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17 Suppl 5():v64-7 (2006) PMID 16807466 </ref><ref name="PMID16807459">Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 Suppl 5():v29-32 (2006) PMID 16807459 </ref><ref name="PMID16608986">Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 17 Suppl 2():ii58-60 (2006) PMID 16608986 </ref><ref name="PMID16670205">A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17(7):1128-33 (2006) PMID 16670205 </ref><ref name="PMID16766586">Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol 17(12):1743-7 (2006) PMID 16766586 </ref><ref name="PMID12562651">Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14(2):242-7 (2003) PMID 12562651 </ref><ref name="PMID11822767">Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12(11):1651-2 (2001) PMID 11822767 </ref><ref name="PMID11106124">Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10):1335-41 (2000) PMID 11106124 </ref><ref name="PMID11142482">Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 11(11):1421-6 (2000) PMID 11142482 </ref><ref name="PMID9636840">A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9(4):457-9 (1998) PMID 9636840 </ref><ref name="PMID20723210">In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 10():441 (2010) PMID 20723210 </ref><ref name="PMID18212755">First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer 98(3):558-63 (2008) PMID 18212755 </ref><ref name="PMID17595658">Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97(3):283-9 (2007) PMID 17595658 </ref><ref name="PMID15266334">Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91(3):489-97 (2004) PMID 15266334 </ref><ref name="PMID12966418">Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89(6):1013-21 (2003) PMID 12966418 </ref><ref name="PMID14676793">Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer 89(12):2190-6 (2003) PMID 14676793 </ref><ref name="PMID12373594">Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87(8):825-33 (2002) PMID 12373594 </ref><ref name="PMID10945489">Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83(4):447-53 (2000) PMID 10945489 </ref><ref name="PMID10362105">Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80(7):981-90 (1999) PMID 10362105 </ref><ref name="PMID19235250">Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250 </ref><ref name="PMID17823908">Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110(9):2027-34 (2007) PMID 17823908 </ref><ref name="PMID17238182">Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer 109(4):727-31 (2007) PMID 17238182 </ref><ref name="PMID12712478">Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97(9):2242-7 (2003) PMID 12712478 </ref><ref name="PMID12879472">Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3):542-53 (2003) PMID 12879472 </ref><ref name="PMID11443620">Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92(1):146-52 (2001) PMID 11443620 </ref><ref name="PMID10526274">Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 86(8):1463-9 (1999) PMID 10526274 </ref><ref name="PMID19688117">Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study. Cancer Res Treat 40(3):116-20 (2008) PMID 19688117 </ref><ref name="PMID15764752">Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 127(3):738-47 (2005) PMID 15764752 </ref><ref name="PMID16002926">Chemotherapy for non-small cell lung cancer in elderly patients. Chest 128(1):132-9 (2005) PMID 16002926 </ref><ref name="PMID16100191">Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128(2):947-57 (2005) PMID 16100191 </ref><ref name="PMID18594002">A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14(13):4213-8 (2008) PMID 18594002 </ref><ref name="PMID15297403">Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10(15):5022-6 (2004) PMID 15297403 </ref><ref name="PMID19362956">Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956 </ref><ref name="PMID19289373">Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. Clin Lung Cancer 10(1):53-7 (2009) PMID 19289373 </ref><ref name="PMID18824450">Weekly paclitaxel in elderly patients (aged &gt; or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 9(5):280-4 (2008) PMID 18824450 </ref><ref name="PMID18650174">An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9(4):235-8 (2008) PMID 18650174 </ref><ref name="PMID14653862">Gemcitabine/carboplatin in advanced non-small-cell lung cancer: data from randomized phase III trials. Clin Lung Cancer 4(2):76-9 (2002) PMID 14653862 </ref><ref name="PMID14662032">The value of platinum compounds in non-small-cell lung cancer. Clin Lung Cancer 3(4):249-53 (2002) PMID 14662032 </ref><ref name="PMID14720349">Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer 3 Suppl 1():S10-6 (2002) PMID 14720349 </ref><ref name="PMID14725730">Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review. Clin Lung Cancer 2 Suppl 1():S11-4 (2000) PMID 14725730 </ref><ref name="PMID20040271">Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204-9 (2009) PMID 20040271 </ref><ref name="PMID110590">A novel SH-type carboxypeptidase in the inner membrane of rat-liver mitochondria. Eur J Biochem 96(1):9-15 (1979) PMID 110590 </ref><ref name="PMID17690124">Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30(6):1186-92 (2007) PMID 17690124 </ref><ref name="PMID16481384">Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 27(5):895-901 (2006) PMID 16481384 </ref><ref name="PMID21047489">Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489 </ref><ref name="PMID20507803">Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803 </ref><ref name="PMID12618501">Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95(5):362-72 (2003) PMID 12618501 </ref><ref name="PMID18827606">Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-8 (2008) PMID 18827606 </ref><ref name="PMID15795320">Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110-8 (2005) PMID 15795320 </ref><ref name="PMID20616908">Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2():209-17 (2009) PMID 20616908 </ref><ref name="PMID19737998">Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14(9):930-5 (2009) PMID 19737998 </ref><ref name="PMID19423674">Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674 </ref><ref name="PMID19221167">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167 </ref><ref name="PMID18263769">Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769 </ref><ref name="PMID17470688">Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12(4):451-64 (2007) PMID 17470688 </ref><ref name="PMID16368866">Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3():1-10 (2005) PMID 16368866 </ref><ref name="PMID10394591">Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4(3):241-51 (1999) PMID 10394591 </ref><ref name="PMID16601104">Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 103(16):6332-7 (2006) PMID 16601104 </ref><ref name="PMID18827853">Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4(3):579-85 (2008) PMID 18827853 </ref><ref name="PMID19690055">Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. Ann Oncol 20(10):1747-8 (2009) PMID 19690055 </ref><ref name="PMID19150937">Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20(5):850-6 (2009) PMID 19150937 </ref><ref name="PMID19088171">An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20(3):486-91 (2009) PMID 19088171 </ref><ref name="PMID18283036">A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19(5):939-45 (2008) PMID 18283036 </ref><ref name="PMID16807472">Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 17 Suppl 5():v86-90 (2006) PMID 16807472 </ref><ref name="PMID16807459">Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 Suppl 5():v29-32 (2006) PMID 16807459 </ref><ref name="PMID15946975">Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy. Ann Oncol 16(7):997-8 (2005) PMID 15946975 </ref><ref name="PMID12598353">ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14(3):455-60 (2003) PMID 12598353 </ref><ref name="PMID12075742">Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13(5):737-41 (2002) PMID 12075742 </ref><ref name="PMID11106124">Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10):1335-41 (2000) PMID 11106124 </ref><ref name="PMID20211022">Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 10():85 (2010) PMID 20211022 </ref><ref name="PMID18667090">Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 8():216 (2008) PMID 18667090 </ref><ref name="PMID17488518">Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer 7():77 (2007) PMID 17488518 </ref><ref name="PMID19658185">Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 115(22):5143-54 (2009) PMID 19658185 </ref><ref name="PMID16258975">Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56 (2005) PMID 16258975 </ref><ref name="PMID12673697">Review of a promising new agent--pemetrexed disodium. Cancer 97(8 Suppl):2056-63 (2003) PMID 12673697 </ref><ref name="PMID19549896">Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69(13):5467-74 (2009) PMID 19549896 </ref><ref name="PMID18594001">Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14(13):4206-12 (2008) PMID 18594001 </ref><ref name="PMID17545550">Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13(11):3413-22 (2007) PMID 17545550 </ref><ref name="PMID17671148">Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 13(15 Pt 2):s4597-601 (2007) PMID 17671148 </ref><ref name="PMID15701857">Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11(2 Pt 1):690-6 (2005) PMID 15701857 </ref><ref name="PMID15217974">Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10(12 Pt 2):4276s-4280s (2004) PMID 15217974 </ref><ref name="PMID15328182">Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 10(16):5439-46 (2004) PMID 15328182 </ref><ref name="PMID20837462">Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 11(5):352-7 (2010) PMID 20837462 </ref><ref name="PMID19632943">Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10(4):252-6 (2009) PMID 19632943 </ref><ref name="PMID14596699">The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer 5(1):21-7 (2003) PMID 14596699 </ref><ref name="PMID14720351">Pemetrexed (Alimta): a new antifolate for non-small-cell lung cancer. Clin Lung Cancer 3 Suppl 1():S22-5 (2002) PMID 14720351 </ref><ref name="PMID19079629">Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 15(6):279-85 (2008) PMID 19079629 </ref><ref name="PMID20040271">Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204-9 (2009) PMID 20040271 </ref><ref name="PMID19336594">First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33(4):915-30 (2009) PMID 19336594 </ref><ref name="PMID21047489">Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489 </ref><ref name="PMID20507803">Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803 </ref><ref name="PMID19917871">American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-66 (2009) PMID 19917871 </ref><ref name="PMID20423465">Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 29():38 (2010) PMID 20423465 </ref><ref name="PMID18827606">Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-8 (2008) PMID 18827606 </ref><ref name="PMID18952704">Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 39(1):27-32 (2009) PMID 18952704 </ref><ref name="PMID20830227">Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med 25(3):294-300 (2010) PMID 20830227 </ref><ref name="PMID17308042">Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404-17 (2007) PMID 17308042 </ref><ref name="PMID18187583">Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73(4):1290-300 (2008) PMID 18187583 </ref><ref name="PMID19737998">Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14(9):930-5 (2009) PMID 19737998 </ref><ref name="PMID19221167">The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167 </ref><ref name="PMID19349511">Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14(4):378-90 (2009) PMID 19349511 </ref><ref name="PMID18263772">Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1():28-36 (2008) PMID 18263772 </ref><ref name="PMID18263770">Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1():14-20 (2008) PMID 18263770 </ref><ref name="PMID18263769">Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769 </ref><ref name="PMID18263768">Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 13 Suppl 1():1-4 (2008) PMID 18263768 </ref><ref name="PMID17673612">Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12(7):808-15 (2007) PMID 17673612 </ref><ref name="PMID16794244">Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11(6):655-65 (2006) PMID 16794244 </ref><ref name="PMID15967829">FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10(6):363-8 (2005) PMID 15967829 </ref><ref name="PMID15821248">Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10(4):282-91 (2005) PMID 15821248 </ref><ref name="PMID11524555">Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4):363-73 (2001) PMID 11524555 </ref><ref name="PMID19851525">Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag 5():781-7 (2009) PMID 19851525 </ref><ref name="PMID18827853">Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4(3):579-85 (2008) PMID 18827853 </ref> | ||
|- | |- | ||
| bgcolor="#dfdfdf" | '''Wichtige Übersichtsartikel''' | | bgcolor="#dfdfdf" | '''Wichtige Übersichtsartikel''' | ||
| Zeile 51: | Zeile 51: | ||
{{LinkWP_Miniartikel|Txt=|Link=}} | {{LinkWP_Miniartikel|Txt=|Link=}} | ||
---- | |||
[http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=PureSearch&db=pubmed&term=19893597,18832554,19956424,19704160,19454467,18790931,18456762,19262443,19262442,20835310,19881166,5058,20859451,20531966,19707410,18831719,19503669,19551884,19658185,19235250,18286507,19182534,19680652,18824424,18852078,18331970,20062690,19809052,19225067,19584208,18321899,19447868,19531624,20008850,19671872,18981003,18483355,19808188,19443337,19443335,19362956,19362951,19632948,19289369,19289368,19073514,18621622,18650168,19546457,20404973,19672420,19079629,20515609,20587343,20038979,19629205,19118231,19336594,21047494,21047489,20507803,19567213,18645621,20354037,19155223,19917871,20433767,19159467,19380411,20539732,20539725,20551407,19088154,20338627,18452692,18437168,20616912,19680293,19726457,19892771,19423674,19221167,19482958,19474164,19357226,19349511,19342473,18779538,18997180,18378542,18586925,18263773,18263772,18263771,18263770,18263769,21165163,19102716,18056854,18552311,18539889,18343515,19027463,21070081,19014447,16470272,20595452,20150572,19690055,19164456,19150937,17938425,18096565,17351253,17322539,17043094,17079694,17071935,16807472,16807471,16807470,16807469,16807466,16807459,16608986,16670205,16766586,12562651,11822767,11106124,11142482,9636840,20723210,18212755,17595658,15266334,12966418,14676793,12373594,10945489,10362105,19235250,17823908,17238182,12712478,12879472,11443620,10526274,19688117,15764752,16002926,16100191,18594002,15297403,19362956,19289373,18824450,18650174,14653862,14662032,14720349,14725730,20040271,110590,17690124,16481384,21047489,20507803,12618501,18827606,15795320,20616908,19737998,19423674,19221167,18263769,17470688,16368866,10394591,16601104,18827853,19690055,19150937,19088171,18283036,16807472,16807459,15946975,12598353,12075742,11106124,20211022,18667090,17488518,19658185,16258975,12673697,19549896,18594001,17545550,17671148,15701857,15217974,15328182,20837462,19632943,14596699,14720351,19079629,20040271,19336594,21047489,20507803,19917871,20423465,18827606,18952704,20830227,17308042,18187583,19737998,19221167,19349511,18263772,18263770,18263769,18263768,17673612,16794244,15967829,15821248,11524555,19851525,18827853, '''ALLE ZITIERTEN ARTIKEL DIREKT IN PUBMED ÖFFNEN'''] | |||
---- | |||
Aktuelle Version vom 23. Dezember 2010, 01:10 Uhr
Bibliographie
- ↑ Adjuvant chemotherapy for completely resected non-small-cell lung cancer. Acta Med Okayama 63(5):223-30 (2009) PMID 19893597
- ↑ Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Am J Respir Crit Care Med 178(8):783-5 (2008) PMID 18832554
- ↑ Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res 1(2):101-14 (2009) PMID 19956424
- ↑ Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol 20(9):1455-7 (2009) PMID 19704160
- ↑ Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4():68-70 (2009) PMID 19454467
- ↑ Challenges treating older non-small cell lung cancer patients. Ann Oncol 19 Suppl 7():vii109-13 (2008) PMID 18790931
- ↑ Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl 2():ii39-40 (2008) PMID 18456762
- ↑ The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 15(1):4-9 (2009) PMID 19262443
- ↑ Current status and future direction of surgical treatment for non-small cell lung cancer. Ann Thorac Cardiovasc Surg 15(1):1-3 (2009) PMID 19262442
- ↑ Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. Ann Thorac Med 5(3):153-60 (2010) PMID 20835310
- ↑ Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients. Ann Thorac Med 4(4):201-7 (2009) PMID 19881166
- ↑ Surface balance study of the interaction between microorganisms and lipid monolayer at the air/water interface. Appl Environ Microbiol 31(4):609-11 (1976) PMID 5058
- ↑ Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. Biologics 4():237-43 (2010) PMID 20859451
- ↑ Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics 4():83-90 (2010) PMID 20531966
- ↑ EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics 3():215-24 (2009) PMID 19707410
- ↑ First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc 2 Suppl 2():S3 (2008) PMID 18831719
- ↑ The role of positron emission tomography in the management of non-small cell lung cancer. Can J Surg 52(3):235-42 (2009) PMID 19503669
- ↑ Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115(18):4156-66 (2009) PMID 19551884
- ↑ 19,0 19,1 Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. Cancer 115(22):5143-54 (2009) PMID 19658185
- ↑ 20,0 20,1 Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 115(9):1924-31 (2009) PMID 19235250
- ↑ Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112(5):1106-13 (2008) PMID 18286507
- ↑ Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther 8(3):206-12 (2009) PMID 19182534
- ↑ Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65(6):1023-8 (2010) PMID 19680652
- ↑ Non-small cell lung cancer staging: proposed revisions to the TNM system. Cancer Imaging 8():181-5 (2008) PMID 18824424
- ↑ PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging 8 Spec No A():S27-31 (2008) PMID 18852078
- ↑ Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging 8():27-35 (2008) PMID 18331970
- ↑ Acute cholangitis due to pancreatic metastasis from squamous cell lung carcinoma: a case report and review of literature. Cases J 2():9113 (2009) PMID 20062690
- ↑ Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest 136(4):1112-8 (2009) PMID 19809052
- ↑ Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135(6):1596-609 (2009) PMID 19225067
- ↑ The new lung cancer staging system. Chest 136(1):260-71 (2009) PMID 19584208
- ↑ Staging of lung cancer. Chest 133(3):593-5 (2008) PMID 18321899
- ↑ Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9 (2009) PMID 19447868
- ↑ Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 15(13):4493-8 (2009) PMID 19531624
- ↑ ***ENG*** Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 15(24):7502-7509 (2009) PMID 20008850
- ↑ Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15(16):5040-8 (2009) PMID 19671872
- ↑ Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 14(21):7060-7 (2008) PMID 18981003
- ↑ Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10):2895-9 (2008) PMID 18483355
- ↑ The role for surgery in stage III non-small-cell lung cancer: can we reliably select the right patients? Clin Lung Cancer 10(5):314-6 (2009) PMID 19808188
- ↑ Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer. Clin Lung Cancer 10(3):174-9 (2009) PMID 19443337
- ↑ Advanced non-small-cell lung cancer in the elderly. Clin Lung Cancer 10(3):158-67 (2009) PMID 19443335
- ↑ 41,0 41,1 Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens. Clin Lung Cancer 10(2):124-9 (2009) PMID 19362956
- ↑ Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer 10(2):91-8 (2009) PMID 19362951
- ↑ Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10(4):281-9 (2009) PMID 19632948
- ↑ Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10(1):28-35 (2009) PMID 19289369
- ↑ Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clin Lung Cancer 10(1):20-7 (2009) PMID 19289368
- ↑ New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. Clin Lung Cancer 9(6):326-30 (2008) PMID 19073514
- ↑ Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results. Clin Lung Cancer 9(3):141-3 (2008) PMID 18621622
- ↑ Mortality related to neoadjuvant therapy and surgery for stage III non-small-cell lung cancer. Clin Lung Cancer 9(4):213-6 (2008) PMID 18650168
- ↑ Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancer. CMAJ 180(13):1326-8 (2009) PMID 19546457
- ↑ Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17(2):13-23 (2010) PMID 20404973
- ↑ Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 16(4):9-21 (2009) PMID 19672420
- ↑ 52,0 52,1 Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 15(6):279-85 (2008) PMID 19079629
- ↑ Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes. Discov Med 9(48):411-7 (2010) PMID 20515609
- ↑ Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 9(49):538-45 (2010) PMID 20587343
- ↑ Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int 106(49):809-18; quiz 819-20 (2009) PMID 20038979
- ↑ Adjuvant chemotherapy after complete resection of non-small cell lung cancer. Dtsch Arztebl Int 105(14):249-54 (2008) PMID 19629205
- ↑ Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33(1):201-12 (2009) PMID 19118231
- ↑ 58,0 58,1 First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 33(4):915-30 (2009) PMID 19336594
- ↑ Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):71-9 (2010) PMID 21047494
- ↑ 60,0 60,1 60,2 Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14(Suppl. 2):33-9 (2010) PMID 21047489
- ↑ 61,0 61,1 61,2 Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 14 Suppl 1():47-53 (2010) PMID 20507803
- ↑ Erlotinib for the treatment of relapsed non-small cell lung cancer. Health Technol Assess 13 Suppl 1():41-7 (2009) PMID 19567213
- ↑ Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5(4):209-17 (2008) PMID 18645621
- ↑ In elderly patients with lung cancer is resection justified in terms of morbidity, mortality and residual quality of life? Interact Cardiovasc Thorac Surg 10(6):1015-21 (2010) PMID 20354037
- ↑ Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival? Interact Cardiovasc Thorac Surg 8(4):467-73 (2009) PMID 19155223
- ↑ 66,0 66,1 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27(36):6251-66 (2009) PMID 19917871
- ↑ Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3():18 (2010) PMID 20433767
- ↑ Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2():2 (2009) PMID 19159467
- ↑ Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 50 Suppl 1():31S-42S (2009) PMID 19380411
- ↑ American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 6(1):39-43 (2010) PMID 20539732
- ↑ Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6(1):12-8 (2010) PMID 20539725
- ↑ Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA 303(23):2368-76 (2010) PMID 20551407
- ↑ Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 39(3):137-50 (2009) PMID 19088154
- ↑ Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375(9722):1267-77 (2010) PMID 20338627
- ↑ Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584-94 (2008) PMID 18452692
- ↑ Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 Suppl 2():S16-22 (2008) PMID 18437168
- ↑ Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. Onco Targets Ther 2():251-60 (2009) PMID 20616912
- ↑ Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1():S24-31 (2009) PMID 19680293
- ↑ Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14(9):909-20 (2009) PMID 19726457
- ↑ The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 14(11):1116-30 (2009) PMID 19892771
- ↑ 81,0 81,1 Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14(5):497-510 (2009) PMID 19423674
- ↑ 82,0 82,1 82,2 The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14(3):253-63 (2009) PMID 19221167
- ↑ Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14(6):601-11 (2009) PMID 19482958
- ↑ Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14(6):612-20 (2009) PMID 19474164
- ↑ Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14(4):399-411 (2009) PMID 19357226
- ↑ 86,0 86,1 Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14(4):378-90 (2009) PMID 19349511
- ↑ The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer. Oncologist 14(4):412-24 (2009) PMID 19342473
- ↑ Consensus conference: multimodality management of early- and intermediate-stage non-small cell lung cancer. Oncologist 13(9):945-53 (2008) PMID 18779538
- ↑ Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76 (2008) PMID 18997180
- ↑ Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist 13(3):309-19 (2008) PMID 18378542
- ↑ Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects. Oncologist 13(6):700-8 (2008) PMID 18586925
- ↑ Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13 Suppl 1():37-46 (2008) PMID 18263773
- ↑ 93,0 93,1 Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 Suppl 1():28-36 (2008) PMID 18263772
- ↑ Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 13 Suppl 1():21-7 (2008) PMID 18263771
- ↑ 95,0 95,1 Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 13 Suppl 1():14-20 (2008) PMID 18263770
- ↑ 96,0 96,1 96,2 Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13 Suppl 1():5-13 (2008) PMID 18263769
- ↑ ***ENG*** EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1(7):497-514 (2010) PMID 21165163
- ↑ EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics 10(1):59-68 (2009) PMID 19102716
- ↑ Nodal metastasis in non-small cell lung cancer: accuracy of 3.0-T MR imaging. Radiology 246(2):596-604 (2008) PMID 18056854
- ↑ Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology 248(2):632-42 (2008) PMID 18552311
- ↑ Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248(2):643-54 (2008) PMID 18539889
- ↑ Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87(1):17-23 (2008) PMID 18343515
- ↑ Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 35(6):590-6 (2008) PMID 19027463
- ↑ CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 9(6):589-96 (2010) PMID 21070081
- ↑ Lung adenocarcinoma presenting as obstructive jaundice: a case report and review of literature. World J Surg Oncol 6():120 (2008) PMID 19014447
- ↑ Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35(1):33-7 (2006) PMID 16470272
- ↑ Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 22(1):132-8 (2011) PMID 20595452
- ↑ Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21(9):1804-9 (2010) PMID 20150572
- ↑ 109,0 109,1 Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. Ann Oncol 20(10):1747-8 (2009) PMID 19690055
- ↑ Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20(5):835-41 (2009) PMID 19164456
- ↑ 111,0 111,1 Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial. Ann Oncol 20(5):850-6 (2009) PMID 19150937
- ↑ Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19(1):115-22 (2008) PMID 17938425
- ↑ Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19(4):739-45 (2008) PMID 18096565
- ↑ Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol 18(5):903-8 (2007) PMID 17351253
- ↑ The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 18(3):453-60 (2007) PMID 17322539
- ↑ Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 18(1):110-5 (2007) PMID 17043094
- ↑ Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317-23 (2007) PMID 17079694
- ↑ Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18(2):324-30 (2007) PMID 17071935
- ↑ 119,0 119,1 Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 17 Suppl 5():v86-90 (2006) PMID 16807472
- ↑ Non-platinum combination of gemcitabine in NSCLC. Ann Oncol 17 Suppl 5():v82-5 (2006) PMID 16807471
- ↑ Non-small-cell lung cancer: which platinum for gemcitabine? Ann Oncol 17 Suppl 5():v79-81 (2006) PMID 16807470
- ↑ Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 17 Suppl 5():v72-8 (2006) PMID 16807469
- ↑ First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17 Suppl 5():v64-7 (2006) PMID 16807466
- ↑ 124,0 124,1 Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 17 Suppl 5():v29-32 (2006) PMID 16807459
- ↑ Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 17 Suppl 2():ii58-60 (2006) PMID 16608986
- ↑ A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17(7):1128-33 (2006) PMID 16670205
- ↑ Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art. Ann Oncol 17(12):1743-7 (2006) PMID 16766586
- ↑ Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14(2):242-7 (2003) PMID 12562651
- ↑ Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12(11):1651-2 (2001) PMID 11822767
- ↑ 130,0 130,1 Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11(10):1335-41 (2000) PMID 11106124
- ↑ Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 11(11):1421-6 (2000) PMID 11142482
- ↑ A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann Oncol 9(4):457-9 (1998) PMID 9636840
- ↑ In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 10():441 (2010) PMID 20723210
- ↑ First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer 98(3):558-63 (2008) PMID 18212755
- ↑ Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97(3):283-9 (2007) PMID 17595658
- ↑ Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 91(3):489-97 (2004) PMID 15266334
- ↑ Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer 89(6):1013-21 (2003) PMID 12966418
- ↑ Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer 89(12):2190-6 (2003) PMID 14676793
- ↑ Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87(8):825-33 (2002) PMID 12373594
- ↑ Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 83(4):447-53 (2000) PMID 10945489
- ↑ Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80(7):981-90 (1999) PMID 10362105
- ↑ Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 110(9):2027-34 (2007) PMID 17823908
- ↑ Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer 109(4):727-31 (2007) PMID 17238182
- ↑ Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial. Cancer 97(9):2242-7 (2003) PMID 12712478
- ↑ Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3):542-53 (2003) PMID 12879472
- ↑ Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92(1):146-52 (2001) PMID 11443620
- ↑ Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 86(8):1463-9 (1999) PMID 10526274
- ↑ Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced Non-Small Cell Lung Cancer: a feasibility study. Cancer Res Treat 40(3):116-20 (2008) PMID 19688117
- ↑ Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 127(3):738-47 (2005) PMID 15764752
- ↑ Chemotherapy for non-small cell lung cancer in elderly patients. Chest 128(1):132-9 (2005) PMID 16002926
- ↑ Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128(2):947-57 (2005) PMID 16100191
- ↑ A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14(13):4213-8 (2008) PMID 18594002
- ↑ Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10(15):5022-6 (2004) PMID 15297403
- ↑ Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. Clin Lung Cancer 10(1):53-7 (2009) PMID 19289373
- ↑ Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study. Clin Lung Cancer 9(5):280-4 (2008) PMID 18824450
- ↑ An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9(4):235-8 (2008) PMID 18650174
- ↑ Gemcitabine/carboplatin in advanced non-small-cell lung cancer: data from randomized phase III trials. Clin Lung Cancer 4(2):76-9 (2002) PMID 14653862
- ↑ The value of platinum compounds in non-small-cell lung cancer. Clin Lung Cancer 3(4):249-53 (2002) PMID 14662032
- ↑ Gemcitabine-based doublets for advanced non-small-cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer 3 Suppl 1():S10-6 (2002) PMID 14720349
- ↑ Gemcitabine and carboplatin in advanced non small-cell lung cancer: a review. Clin Lung Cancer 2 Suppl 1():S11-4 (2000) PMID 14725730
- ↑ 161,0 161,1 Second and third line treatment in advanced non-small cell lung cancer. Discov Med 8(43):204-9 (2009) PMID 20040271
- ↑ A novel SH-type carboxypeptidase in the inner membrane of rat-liver mitochondria. Eur J Biochem 96(1):9-15 (1979) PMID 110590
- ↑ Chemotherapy improves low performance status lung cancer patients. Eur Respir J 30(6):1186-92 (2007) PMID 17690124
- ↑ Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 27(5):895-901 (2006) PMID 16481384
- ↑ Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95(5):362-72 (2003) PMID 12618501
- ↑ 166,0 166,1 Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112-8 (2008) PMID 18827606
- ↑ Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110-8 (2005) PMID 15795320
- ↑ Gemcitabine for the treatment of advanced nonsmall cell lung cancer. Onco Targets Ther 2():209-17 (2009) PMID 20616908
- ↑ 169,0 169,1 Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist 14(9):930-5 (2009) PMID 19737998
- ↑ Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12(4):451-64 (2007) PMID 17470688
- ↑ Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10 Suppl 3():1-10 (2005) PMID 16368866
- ↑ Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 4(3):241-51 (1999) PMID 10394591
- ↑ Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A 103(16):6332-7 (2006) PMID 16601104
- ↑ 174,0 174,1 Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 4(3):579-85 (2008) PMID 18827853
- ↑ An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 20(3):486-91 (2009) PMID 19088171
- ↑ A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19(5):939-45 (2008) PMID 18283036
- ↑ Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy. Ann Oncol 16(7):997-8 (2005) PMID 15946975
- ↑ ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14(3):455-60 (2003) PMID 12598353
- ↑ Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13(5):737-41 (2002) PMID 12075742
- ↑ Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 10():85 (2010) PMID 20211022
- ↑ Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 8():216 (2008) PMID 18667090
- ↑ Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer 7():77 (2007) PMID 17488518
- ↑ Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56 (2005) PMID 16258975
- ↑ Review of a promising new agent--pemetrexed disodium. Cancer 97(8 Suppl):2056-63 (2003) PMID 12673697
- ↑ Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69(13):5467-74 (2009) PMID 19549896
- ↑ Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14(13):4206-12 (2008) PMID 18594001
- ↑ Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 13(11):3413-22 (2007) PMID 17545550
- ↑ Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 13(15 Pt 2):s4597-601 (2007) PMID 17671148
- ↑ Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11(2 Pt 1):690-6 (2005) PMID 15701857
- ↑ Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 10(12 Pt 2):4276s-4280s (2004) PMID 15217974
- ↑ Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 10(16):5439-46 (2004) PMID 15328182
- ↑ Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. Clin Lung Cancer 11(5):352-7 (2010) PMID 20837462
- ↑ Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 10(4):252-6 (2009) PMID 19632943
- ↑ The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer 5(1):21-7 (2003) PMID 14596699
- ↑ Pemetrexed (Alimta): a new antifolate for non-small-cell lung cancer. Clin Lung Cancer 3 Suppl 1():S22-5 (2002) PMID 14720351
- ↑ Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 29():38 (2010) PMID 20423465
- ↑ Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 39(1):27-32 (2009) PMID 18952704
- ↑ Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med 25(3):294-300 (2010) PMID 20830227
- ↑ Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 6(2):404-17 (2007) PMID 17308042
- ↑ Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73(4):1290-300 (2008) PMID 18187583
- ↑ Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 13 Suppl 1():1-4 (2008) PMID 18263768
- ↑ Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 12(7):808-15 (2007) PMID 17673612
- ↑ Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11(6):655-65 (2006) PMID 16794244
- ↑ FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 10(6):363-8 (2005) PMID 15967829
- ↑ Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab. Oncologist 10(4):282-91 (2005) PMID 15821248
- ↑ Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6(4):363-73 (2001) PMID 11524555
- ↑ Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag 5():781-7 (2009) PMID 19851525
Andere Lexika
ALLE ZITIERTEN ARTIKEL DIREKT IN PUBMED ÖFFNEN